- Home
- SDOT vs MEIP Comparison
SDOT vs MEIP Comparison
Compare SDOT & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- MEIP
- Stock Information
- Founded
- SDOT 2014
- MEIP 2000
- Country
- SDOT United States
- MEIP United States
- Employees
- SDOT N/A
- MEIP N/A
- Industry
- SDOT Restaurants
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- SDOT Consumer Discretionary
- MEIP Health Care
- Exchange
- SDOT Nasdaq
- MEIP Nasdaq
- Market Cap
- SDOT 21.5M
- MEIP 19.5M
- IPO Year
- SDOT 2020
- MEIP 2003
- Fundamental
- Price
- SDOT $3.38
- MEIP $2.78
- Analyst Decision
- SDOT Hold
- MEIP Hold
- Analyst Count
- SDOT 1
- MEIP 2
- Target Price
- SDOT N/A
- MEIP $7.00
- AVG Volume (30 Days)
- SDOT 66.5K
- MEIP 53.1K
- Earning Date
- SDOT 11-12-2024
- MEIP 11-12-2024
- Dividend Yield
- SDOT N/A
- MEIP N/A
- EPS Growth
- SDOT N/A
- MEIP N/A
- EPS
- SDOT 0.35
- MEIP N/A
- Revenue
- SDOT $655,938,000.00
- MEIP N/A
- Revenue This Year
- SDOT N/A
- MEIP N/A
- Revenue Next Year
- SDOT $11.33
- MEIP $300.00
- P/E Ratio
- SDOT $9.64
- MEIP N/A
- Revenue Growth
- SDOT N/A
- MEIP 33.76
- 52 Week Low
- SDOT $2.24
- MEIP $2.61
- 52 Week High
- SDOT $7.00
- MEIP $6.91
- Technical
- Relative Strength Index (RSI)
- SDOT 51.22
- MEIP 36.75
- Support Level
- SDOT $2.83
- MEIP $2.76
- Resistance Level
- SDOT $4.10
- MEIP $2.91
- Average True Range (ATR)
- SDOT 0.40
- MEIP 0.11
- MACD
- SDOT 0.04
- MEIP -0.04
- Stochastic Oscillator
- SDOT 44.75
- MEIP 5.13
About SDOT Sadot Group Inc.
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China, and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.